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Accepted 21 February 2014Posterior reversible encephalopathy syndrome (PRES) is characterised by headache, visual disorders, sei-
zures, altered mentation, consciousness disturbances and focal neurological signs. Initially described in
patients with pre and eclampsia, severe hypertension, posterior reversible encephalopathy syndrome
can occur in other clinical conditions such as infection, sepsis, shock, cancer chemotherapy, autoimmune
diseases and hypercalcemia. Pathogenesis of brain lesions in PRES is not full understood and two opposite
theories have been proposed. Both models are based on the central role of hypertension. According to the
ﬁrst theory, hypertension could cause a breakdown of the autoregulatory system in cerebral circulation,
leading to brain edema. The second theory suggests that hypertension causes activation of autoregulatory
system, which ﬁnally results in a vasoconstriction of brain vessels with hypoperfusion, ischemia and sub-
sequent ﬂuid leakage. However a large number of patients, with PRES, doesn’t show hypertension. We
here describe the hypothesis of the crucial role of endothelial dysfunction and activation in PRES patho-
genesis. Our hypothesis offers a common pathogenetic mechanism in which every PRES-related condition
can be set. In our model, the activation of immune system and the consequent endothelial activation start
a molecular cascade which ﬁnally causes the production of molecules which alter the normal homeosta-
sis of blood–brain barrier. This alteration consists in a weakening of brain vessel tight junctions, which
allows ﬂuid leakage and edema. In this scenario, hypertension would be an epiphenomenon of the under-
lying mechanism and not the cause and, for this reason, it can be present or not in PRES.
 2014 Elsevier Ltd. All rights reserved.Introduction
Posterior reversible encephalopathy syndrome (PRES) is charac-
terised by headache, visual disorders, seizures, altered mentation,
consciousness disturbances, and focal neurological signs [1]. Ini-
tially described in pre- and eclampsia, use of cyclosporine after
transplantation, and severe hypertension, PRES can occur in many
other clinical conditions such as infection, sepsis, shock, cancer
chemotherapy, autoimmune diseases, and hypercalcaemia.
PRES shows a typical neuroradiological distribution of brain le-
sions; RMN images, in fact, reveal symmetrical areas of vasogenic
edema of the white matter predominately localized in the territo-
ries of posterior circulation [2] even if signal alteration can involve,
in most severe cases, other brain regions such as temporal and
frontal lobes, basal ganglia, cerebellum, or brainstem [3].Promptly recognized, symptoms and radiologic abnormalities of
PRES may completely resolve; when unrecognized, the syndrome
could progress to ischemia, brain infarction and death.
Pathogenesis of brain lesions in PRES is not fully understood
and two opposite theories have been proposed so far [4]. The ﬁrst
andmost popular theory is that of hypertension/hyperperfusion: in
50–70% of cases, PRES patients show a moderate-to-severe eleva-
tion of blood pressure; this ﬁnding initially suggested the hypoth-
esis that hypertension could cause a breakdown of the
autoregulatory system in cerebral circulation, leading to brain ede-
ma. Autoregulation is an intrinsic property of cerebral vessels
which maintains the blood ﬂow constant; in fact, a vasoconstric-
tion occurs when blood pressure drops, whereas a vasodilatation
is activated as blood pressure increases. This property is mediated
by the endothelium itself through the release of relaxing (nitric
oxide) or vasoconstriction (thromboxane A-2 and endothelin)
agents. The second theory suggests that hypertension causes the
activation of autoregulatory system, which ﬁnally results in a vaso-
constriction of brain vessels with hypoperfusion, ischemia and
subsequent ﬂuid leakage.
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several clinical ﬁndings remain unexplained; in fact, a large num-
ber of PRES patients doesn’t show hypertension and in many other
cases, blood pressure doesn’t exceed autoregulatory upper limit,
suggesting a more general mechanism in PRES pathogenesis. More-
over, the extent of brain edema doesn’t appear to correlate with
the increase of blood pressure.Hypothesis
We here describe the hypothesis of the crucial role of endothe-
lial dysfunction and activation in PRES pathogenesis; in this model,
hypertension is only an epiphenomenon of the underlying mecha-
nism of endothelial activation which would be, in our opinion, the
common ﬁnal pathway of all clinical conditions precipitating PRES
onset.
Evaluation of the hypotheses
Endothelial activation and damage in PRES onset
Our hypothesis rises from the observation that clinical condi-
tions in which PRES can occur share some common features basi-
cally consisting in an activation of the immune system. Toxemia
of pregnancy, autoimmune diseases, sepsis, transplantation, post-
cancer chemotherapy are all systemic processes involving the en-
tire organism which responses through its fundamental tools, i.e.
the cells of the immune system and cytokines. T-lymphocytes, in
particular, seem to have a pivotal role in driving and coordinating
the immune response in PRES-related conditions along with mole-
cules as tumor necrosis factor (TNF)-a, interleukin (IL)-1, and
interferon (IFN)-c. The immune system would be responsible, in
our hypothesis, of a systemic endothelial activation which eventu-
ally results in an increased vasal permeability; in this contest, PRES
would represent the neurological manifestation of a more complex
systemic process.
Molecular basis of endothelial damage in PRES
Immune system is activated every time an injury affects the
organism; its effects can be exerted through the release of speciﬁc
molecules, i.e. cytokines, which regulate the immune response and
cause alterations in the normal homeostasis of tissues and organs.
A central role is played by vasculature which is one of the most
important target of the immune response. Changes in endothelial
function and structure allow leucocytes to reach the sites where
their activity is needed; but to do that, vessels have to express sur-
face receptors to bind the cells and modify the intercellular junc-
tion to increase permeability and make cells pass through.
Leukocytes recruitment and vascular permeability have to be
therefore coordinated and it is not surprising that cytokines, which
have pleiotropic functions, control both activities. TNF-a and IL-1,
in particular, induce the expression of adhesion molecules such as
intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion
molecule (VCAM-1), E-selectin, which are markers of endothelial
activation. Leukocytes are sequestrated by activated endothelium
and release cytotoxic mediators such as reactive oxygen species
(ROS) and proteases, contributing to endothelial damage and sub-
sequent ﬂuid leakage. TNF-a can also induce the expression of vas-
cular endothelial growth factor (VEGF), an important regulator of
angiogenesis and vascular permeability; in addition, TNF-a is able
to switch the expression of VEGF forms from anti-angiogenic splice
variants to angiogenic ones [5]. Notably, VEGF induces ICAM-1,
VCAM-1, and E-selectin expression in endothelial cells during
inﬂammation, thus conﬁrming the close functional relationship
of these molecules in the inﬂammatory response [6]. Recently
VEGF-A has been identiﬁed as an important driver of blood–brainbarrier (BBB) permeability, lymphocytes inﬁltration, tissue dam-
age, and clinical deﬁcit. Argaw et al. have demonstrated that IL-1
b induces atrocytes to express molecules favoring vessel plasticity
including hypoxia-induced factor 1a (HIF-1a) and its target gene
coding for VEGF-A; this study also conﬁrmed VEGF to be a potent
inducer of BBB permeability. VEGF weakens tight junctions in brain
endothelial cells, acting on claudins and occludins, which play key
roles in junction formation and properties [7]. VEGF can also acti-
vate the Vesiculo-Vacuolar Organelle (VVO) which is supposed to
provide the major route of extravasation of ﬂuids and macromole-
cules [8] (Fig. 1).
The activation of immune system in PRES-related conditions
causes the release of cytokines which up-regulate the expression
of VEGF, opening the way to brain edema; notably, in preeclamp-
sia, one of the ﬁrst studied and most common clinical condition
in which PRES can occur, circulating levels of VEGF-A are increased
and preeclamptic plasma results in a 5-fold acute increase in vas-
cular permeability [9].
Hypertension, in our opinion, would be a consequence and not
the primum movens in PRES pathogenesis, due to endothelial dys-
function and activation determined by immune response; endo-
thelial dysfunction consists in a insufﬁcient production of nitric
oxide (NO), a potent vasodilator, in response to stimuli that usually
would cause a release of this factor. Another contributing factor to
determine hypertension would be the endothelial activation which
cause an altered cell trafﬁcking through vessels wall, increasing
cell adhesion and narrowing vasal lumen of microvasculature. This
deﬁcit of microvasculature also accounts for the microangiopathic
haemolysis registered in many PRES-related conditions, causing
the release in the circulation of red cells product such as lactate
serum dehydrogenase (LDH). LDH is an intracellular enzyme which
is present in many tissues; its concentration is about 500-fold low-
er in serum than in body cells. Tissue damage results in an enzyme
release with a consequent increase in serum LDH activity [10].
Endothelial injuries may cause a narrowing of blood vessels and
modiﬁcations in endothelial wall which make erythrocytes ﬂow
difﬁcult leading to red cells mechanical stress and intracellular
content release. Many clinical observations suggest the endothelial
involvement in PRES pathogenesis. Schwartz et al. reported an
association between PRES-related brain edema and serum LDH lev-
els in patients with pre- and eclampsia but not in pre- and eclamp-
tic patients who didn’t show neuroradiological abnormalities
compatible with PRES. Moreover, schistocytes were found in
peripheral smear thus supporting the hypothesis of the microang-
iopathic status in PRES patients [11]. Demirtas et al. also found in-
creased levels of serum LDH in pre- and eclamptic patients with
magnetic resonance imaging suggestive of PRES [12]. Finally, Fin-
occhi et al. [13] and Vargas et al. [14] demonstrated a signiﬁcant
raising in serum LDH activity in obstetric patients prior of the clin-
ical onset of PRES symptoms. Microangiopathic status would
determine a reduced perfusion of tissues and organs and subse-
quent hypoxia would further increase VEGF production through
the induction of HIF-1a, especially in nervous system. Further
studies should be conducted to conﬁrm the overexpression of
endothelial activation markers in the other PRES-related condi-
tions in which these molecules have not been investigated so far.
Bartysnki et al. reported increased levels of ICAM-1, VCAM-1, and
E-selectin in different diseases as preeclampsia, allogeneic bone
marrow transplantation (allo-BMT), solid organ transplantation
(SOT), infection, sepsis, and shock [4]. Furthermore, many observa-
tions emphasize the role of VEGF in PRES pathogenesis: brain
biopsy showed endothelial activation, T-cell trafﬁcking, and endo-
thelial/cellular VEGF expression in a case of PRES after cardiac
transplantation [15] and in a patient with a non-Hodgkin lym-
phoma treated with different chemotherapy regimens [16]. Even
PRES in systemic lupus erythematosus (SLE) has been recently
Fig. 1. PRES-related conditions cause the activation of the immune system and the release of cytokines such as TNF-a and IL-1. TNF-a and IL-1 induce the expression of the
adhesion molecules ICAM 1 and VCAM 1 which interact with leukocytes, making them produce reactive oxygen species (ROS) and proteases leading to endothelial damage
and consequent ﬂuid leakage. TNF-a and IL-1 can also induce astrocytes production of VEGF which weakens the tight junction of brain vasculature and activates the Vesiculo-
Vacuolar Organelle (VVO), thus contributing to edema formation.
A. Marra et al. /Medical Hypotheses 82 (2014) 619–622 621supposed to be related with the increased level of VEGF [17],
whose serum concentration was found to correlate with disease
activity in a large number of autoimmune syndromes [18].Consequences and discussion
PRES is a neurological entity that can occur in many clinical
conditions. Promptly recognized, symptoms and radiologic abnor-
malities of PRES may completely resolve; when unrecognized, the
syndrome could progress to ischemia, brain infarction, and death.
Immune response may play a central role in pathophysiology of
PRES patients [4]. In normal conditions, endothelial cells were
highly active, constantly sensing and responding to alterations in
the local extracellular environment. Endothelial cell activation oc-
curred as a normal adaptive response; the nature and duration of
which depends not only on the type of stimulus, but also on the
spatial and temporal dynamics of the system [19]. Endothelial cells
activations may also occur under physiologic and pathophysiologic
conditions. During the inﬂammatory response, the vascular endo-
thelial cells were activated and induced many changes in gene
expression to participate in inﬂammatory processes [20]. Once
activated, the endothelial vascular cells began to secrete cytokines,
chemokines and colony stimulating factors [20].
In the majority of patients who develop PRES, a complex under-
lying ‘systemic process’ was present as T-cell activation, inﬂamma-
tory cytokine production, activation of endothelial surface
antigens, endothelial antibodies, immune system antigens and
VEGF elevation [4]. Cytokines (TNF-a IL-1) up-regulated endothe-
lial surface antigens (P-selectin, E-selectin, ICAM-1, VCAM-1), and
increased leukocyte adherence (trafﬁcking) leading to microcircu-
latory dysfunction. Enhanced systemic endothelial activation
(swelling), leukocyte trafﬁcking, and vasoconstriction, alone or in
combination, would result in brain and systemic hypoperfusion
[4]. Furthermore, in our hypothesis patients with PRES may have
a particular tendency to develop an overexpressed immune re-
sponse associated with increased endothelial susceptibility to
inﬂammatory stimuli.However, PRES pathogenesis is not fully understood and the
theories so far proposed don’t account for all the different cases re-
ported in literature. These previous theories give a central role to
hypertension and autoregulation of blood ﬂow in cerebral circula-
tion. Our hypothesis, on the contrary, offers a common pathoge-
netic mechanism in which every PRES-related condition can be
set; in this model, the activation of immune system and the conse-
quent endothelial activation start a molecular cascade which ﬁnal-
ly causes the production of molecules, i.e. cytokines and VEGF,
which alter the normal homeostasis of BBB; this alteration consists
in a weakening of brain vessel tight junctions which allows ﬂuid
leakage and edema. In this scenario, hypertension would be an epi-
phenomenon of the underlying mechanism and not the cause and,
for this reason, it can be present or not in PRES.
The exact comprehension of PRES pathogenesis is fundamental
to ﬁnd a targeted treatment; nowadays, the only way to contrast
PRES is to treat the precipitating condition that led to syndrome
development. Our hypothesis not only proposes a unifying molec-
ular model of PRES pathogenesis, but, clarifying the complex path-
way through which the syndrome develops, opens new
perspectives to possible interventions. In fact, the action of the
two principal molecules that drive endothelial activation and per-
meability, i.e. TNF-a and VEGF, respectively, could be antagonized
by antibodies and receptor inhibitors yet available in clinical prac-
tice. TNF-a and VEGF, just like markers of endothelial activation
e.g. ICAM-1 and VCAM-1, are not routinely determined in blood
analyses and their measurement may have only an interest in re-
search to clarify the mechanism of PRES pathogenesis in order to
search for a more speciﬁc treatment. LDH, instead, could be a use-
ful marker which can be easily and early detected in clinical rou-
tine to identify patients requiring more attention before the
clinical onset of the syndrome, thus conﬁrming the central role
of endothelial instability in syndrome’s pathogenesis.Competing interests
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